FOR IMMEDIATE RELEASE

OncoFirm™ Diagnostics Strengthens Intellectual Property Portfolio with Six Patent Applications and Three Trademark Filings

New York, NY — August 3, 2026 — OncoFirm™ Diagnostics Corporation today announced a significant milestone in the Company’s intellectual property strategy with the filing of six patent applications and three trademark applications supporting its next-generation rapid cancer diagnostics platform.

These filings represent another important step in establishing a comprehensive intellectual property portfolio designed to protect the Company’s innovations in early cancer detection, proprietary fluorescence-enhanced lateral flow diagnostics, AI-assisted diagnostic analysis, digital diagnostic readers, biomarker technologies, and integrated oncology testing platforms.

As global demand continues to grow for rapid, accessible, and cost-effective cancer diagnostics, OncoFirm™ is strategically positioning itself with proprietary technologies intended to support future commercialization, strategic partnerships, licensing opportunities, and long-term shareholder value.

“Our intellectual property strategy is one of the cornerstones of our business,” said Jonathan Adam Barash, Founder and CEO of OncoFirm™ Diagnostics Corporation. “Filing six patent applications and three trademark applications demonstrates our commitment to building a world-class diagnostics company focused on innovation, scientific excellence, and technologies that have the potential to improve cancer detection worldwide. While this is an important milestone, we believe it is only the beginning.”

The Company’s expanding portfolio is intended to support multiple areas of innovation, including:

• Advanced fluorescence-enhanced lateral flow diagnostic technologies
• Multi-biomarker cancer detection platforms
• AI-assisted diagnostic interpretation
• Digital handheld diagnostic reader systems
• Intelligent oncology software platforms
• Proprietary assay design and biomarker detection methodologies

By strengthening its intellectual property position, OncoFirm™ aims to create meaningful competitive advantages while increasing the long-term value of its technology portfolio for investors, healthcare providers, distribution partners, and future strategic collaborators.

The Company continues to advance product development, research collaborations, regulatory planning, and commercialization initiatives focused on expanding access to rapid point-of-care cancer diagnostics worldwide. The recent filings reinforce OncoFirm’s commitment to developing differentiated diagnostic technologies capable of addressing one of healthcare’s most significant unmet needs—earlier cancer detection.

About OncoFirm™ Diagnostics Corporation

OncoFirm™ Diagnostics Corporation is a biotechnology company focused on developing innovative rapid diagnostic technologies for the early detection of cancer. The Company is building a portfolio of proprietary in vitro diagnostic (IVD) platforms incorporating fluorescence-enhanced lateral flow technology, AI-assisted diagnostic analysis, biomarker discovery, and digital diagnostic readers designed to improve accessibility, speed, and clinical utility across a wide range of healthcare settings. The company’s mission is to make early cancer detection faster, smarter, and more accessible worldwide.

Media & Investor Relations

OncoFirm™ Diagnostics Corporation

Website: https://oncofirmdiagnostics.com

Investor Information: https://oncofirmdiagnostics.com/investor-information

LinkedIn: https://www.linkedin.com/company/oncofirm-diagnostics

Company Updates: https://www.linkedin.com/showcase/oncofirm-diagnostiics/

Email: [email protected]

Investor Relations: [email protected]

Phone: +1 (516) 900-2606

Connect With OncoFirm™

🌐 Website: https://oncofirmdiagnostics.com

💼 LinkedIn: https://www.linkedin.com/company/oncofirm-diagnostics

📢 Follow us for company updates, scientific developments, partnership announcements, and investor news.

Forward-Looking Statements

This press release contains forward-looking statements regarding anticipated research, intellectual property, product development, commercialization activities, regulatory pathways, market opportunities, and future business prospects. Patent applications are subject to examination by the applicable patent offices, and trademark applications remain subject to review and approval by the applicable trademark authorities. Forward-looking statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. OncoFirm™ Diagnostics Corporation undertakes no obligation to update these statements except as required by applicable law.